p53 Deficiency Increases Transformation by v-Abl and Rescues the Ability of a C-Terminally Truncated v-Abl Mutant To Induce Pre-B Lymphoma In Vivo

REFERENCES

• Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R., and Vousden, K. H.. 1998. p14ARF links the tumor suppressors RB and p53. Nature 395:124–125
   PubMed Web of Science ®Google Scholar
• Baxter, E. W., Blyth, K., Donehower, L. A., Cameron, E. R., Onions, D. E., and Neil, J. C.. 1996. Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development? J. Virol. 70:2095–2100
   PubMedGoogle Scholar
• Dai, Z., and Pendergast, A. M.. 1995. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 9:2569–2582
   PubMed Web of Science ®Google Scholar
• Danial, N. N., Losman, J. A., Lu, T., Yip, N., Krishnan, K., Krolewski, J., Goff, S. P., Wang, J. Y., and Rothman, P. B.. 1998. Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation. Mol. Cell. Biol. 18:6795–6804
   PubMedGoogle Scholar
• Danial, N. N., Pernis, A., and Rothman, P. B.. 1995. Jak-STAT signaling induced by the v-abl oncogene. Science 269:1875–1877
   PubMed Web of Science ®Google Scholar
• de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S. Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J., and Lowe, S. W.. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12:2434–2442
   PubMed Web of Science ®Google Scholar
• Donehower, L. A., Godley, L. A., Aldaz, C. M., Pyle, R., Shi, Y. P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H. E.. 1995. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 9:882–895
   PubMed Web of Science ®Google Scholar
• Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A.Jr., Butel, J. S., and Bradley, A.. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–221
   PubMed Web of Science ®Google Scholar
• Goff, S. P.. 1985. The Abelson murine leukemia virus oncogene. Proc. Soc. Exp. Biol. Med. 179:403–412
   PubMedGoogle Scholar
• Goff, S. P., Gilboa, E., Witte, O. N., and Baltimore, D.. 1980. Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell 22:777–785
   PubMed Web of Science ®Google Scholar
• Goi, K., Takagi, M., Iwata, S., Delia, D., Asada, M., Donghi, R., Tsunematsu, Y., Nakazawa, S., Yamamoto, H., Yokota, J., Tamura, K., Saeki, Y., Utsunomiya, J., Takahashi, T., Ueda, R., Ishioka, C., Eguchi, M., Kamata, N., and Mizutani, S.. 1997. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res. 57:1895–1902
   PubMed Web of Science ®Google Scholar
• Green, P. L., Kaehler, D. A., Bennett, L. M., and Risser, R.. 1989. Multiple steps are required for the induction of tumors by Abelson murine leukemia virus. J. Virol. 63:1989–1994
   PubMedGoogle Scholar
• Green, P. L., Kaehler, D. A., and Risser, R.. 1987. Clonal dominance and progression in Abelson murine leukemia virus lymphomagenesis. J. Virol. 61:2192–2197
   PubMedGoogle Scholar
• Hevezi, P., Alin, K., and Goff, S. P.. 1993. Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes. Oncogene 8:2413–2423
   PubMedGoogle Scholar
• Hevezi, P., Alin, K., Rees-Jones, R., and Goff, S. P.. 1992. Bone marrow-transforming activity of linker insertion mutants of Abelson murine leukemia virus. Oncogene 7:2323–2328
   PubMedGoogle Scholar
• Huang, T. S., Kuo, M. L., Shew, J. Y., Chou, Y. W., and Yang, W. K.. 1996. Distinct p53-mediated G1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents. Oncogene 13:625–632
   PubMedGoogle Scholar
• Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A.. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1–7
   PubMed Web of Science ®Google Scholar
• Kantor, A. B., Stall, A. M., Adams, S., and Herzenberg, L. A.. 1992. Differential development of progenitor activity for three B-cell lineages. Proc. Natl. Acad. Sci. USA 89:3320–3324
   PubMed Web of Science ®Google Scholar
• Ko, L. J., and Prives, C.. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054–1072
   PubMed Web of Science ®Google Scholar
• Laneuville, P.. 1995. Abl tyrosine protein kinase. Semin. Immunol. 7:255–66
   PubMedGoogle Scholar
• Levine, A. J.. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331
   PubMed Web of Science ®Google Scholar
• Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., and Lowe, S. W.. 1998. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12:3008–3019
   PubMed Web of Science ®Google Scholar
• Linardopoulos, S., Street, A. J., Quelle, D. E., Parry, D., Peters, G., Sherr, C. J., and Balmain, A.. 1995. Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Res. 55:5168–5172
   PubMed Web of Science ®Google Scholar
• Lloyd, A. C., Obermuller, F., Staddon, S., Barth, C. F., McMahon, M., and Land, H.. 1997. Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 11:663–677
   PubMedGoogle Scholar
• Lowe, S. W., Jacks, T., Housman, D. E., and Ruley, H. E.. 1994. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA 91:2026–2030
   PubMed Web of Science ®Google Scholar
• Murtagh, K., Skladany, G., Hoag, J., and Rosenberg, N.. 1986. Abelson murine leukemia virus variants with increased oncogenic potential. J. Virol. 60:599–606
   PubMedGoogle Scholar
• Palmero, I., Pantoja, C., and Serrano, M.. 1998. p19ARF links the tumor suppressor p53 to Ras. Nature 395:125–126
   PubMed Web of Science ®Google Scholar
• Parmar, K., Huebner, R. C., and Rosenberg, N.. 1991. Carboxyl-terminal determinants of Abelson protein important for lymphoma induction. J. Virol. 65:6478–6485
   PubMedGoogle Scholar
• Quelle, D. E., Ashmun, R. A., Hannon, G. J., Rehberger, P. A., Trono, D., Richter, K. H., Walker, C., Beach, D., Sherr, C. J., and Serrano, M.. 1995. Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11:635–645
   PubMed Web of Science ®Google Scholar
• Radfar, A., Unnikrishnan, I., Lee, H. W., DePinho, R. A., and Rosenberg, N.. 1998. p19(Arf) induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc. Natl. Acad. Sci. USA 95:13194–13199
   PubMed Web of Science ®Google Scholar
• Renshaw, M. W., Kipreos, E. T., Albrecht, M. R., and Wang, J. Y.. 1992. Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth, depending on the cell context. EMBO J. 11:3941–3951
   PubMed Web of Science ®Google Scholar
• Rosenberg, N.. 1982. Abelson leukemia virus. Curr. Top. Microbiol. Immunol. 101:95–126
   PubMed Web of Science ®Google Scholar
• Rosenberg, N., and Baltimore, D.. 1976. A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J. Exp. Med. 143:1453–1463
   PubMed Web of Science ®Google Scholar
• Rosenberg, N., and Witte, O.. 1988. The viral and cellular forms of the Abelson (abl) oncogene. Adv. Virus. Res. 35:39–81
   PubMed Web of Science ®Google Scholar
• Rosenberg, N. E., Clark, D. R., and Witte, O. N.. 1980. Abelson murine leukemia virus mutants deficient in kinase activity and lymphoid cell transformation. J. Virol. 36:766–774
   PubMedGoogle Scholar
• Scher, C. D., and Siegler, R.. 1975. Direct transformation of 3T3 cells by Abelson murine leukaemia virus. Nature 253:729–731
   PubMed Web of Science ®Google Scholar
• Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W.. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593–602
   PubMed Web of Science ®Google Scholar
• Sherr, C. J.. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:2984–2991
   PubMed Web of Science ®Google Scholar
• Shi, Y., Alin, K., and Goff, S. P.. 1995. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev 9:2583–2597
   PubMed Web of Science ®Google Scholar
• Shick, L., Carman, J. H., Choi, J. K., Somasundaram, K., Burrell, M., Hill, D. E., Zeng, Y. X., Wang, Y., Wiman, K. G., Salhany, K., Kadesch, T. R., Monroe, J. G., Donehower, L. A., and el-Deiry, W. S.. 1997. Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice. Cell Growth Differ. 8:121–131
   PubMedGoogle Scholar
• Skorski, T., Nieborowska-Skorska, M., Wlodarski, P., Perrotti, D., Martinez, R., Wasik, M. A., and Calabretta, B.. 1996. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc. Natl. Acad. Sci. USA 93:13137–13142
   PubMed Web of Science ®Google Scholar
• Southern, E. M.. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503–517
   PubMed Web of Science ®Google Scholar
• Thome, K. C., Radfar, A., and Rosenberg, N.. 1997. Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. J. Virol. 71:8149–8156
   PubMed Web of Science ®Google Scholar
• Unnikrishnan, I., Radfar, A., Jenab-Wolcott, J., and Rosenberg, N.. 1999. p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. Mol. Cell. Biol. 19:4825–4831
   PubMedGoogle Scholar
• Wang, J.. 1993. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr. Opin. Genet. Dev. 3:35–43
   PubMedGoogle Scholar
• Wong, K. K., Zou, X., Merrell, K. T., Patel, A. J., Marcu, K. B., Chellappan, S., and Calame, K.. 1995. v-Abl activates c-myc transcription through the E2F site. Mol. Cell. Biol. 15:6535–6544
   PubMedGoogle Scholar
• Ziegler, S. F., Whitlock, C. A., Goff, S. P., Gifford, A., and Witte, O. N.. 1981. Lethal effect of the Abelson murine leukemia virus transforming gene product. Cell 27:477–486
   PubMedGoogle Scholar
• Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F.. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424–2433
   PubMed Web of Science ®Google Scholar
• Zou, X., and Calame, K.. 1999. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J. Biol. Chem. 274:18141–18144
   PubMed Web of Science ®Google Scholar
• Zou, X., Rudchenko, S., Wong, K., and Calame, K.. 1997. Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases. Genes Dev. 11:654–662
   PubMedGoogle Scholar